| Kirsti Malinchok, MS, CCC-SLP | |
|
11301 Wilshire Blvd, Los Angeles, CA 90073-1003 | |
| (310) 478-3711 | |
| Not Available |
| Full Name | Kirsti Malinchok |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 11301 Wilshire Blvd, Los Angeles, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013697408 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 33975 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kirsti Malinchok, MS, CCC-SLP 11301 Wilshire Blvd, Los Angeles, CA 90073-1003 Ph: (310) 478-3711 | Kirsti Malinchok, MS, CCC-SLP 11301 Wilshire Blvd, Los Angeles, CA 90073-1003 Ph: (310) 478-3711 |
News Archive
In early 2007, Northwestern University chemist Karl Scheidt's interest was piqued when marine chemist Amy Wright reported in the Journal of Natural Products that a new natural compound derived from an uncommon deep-sea sponge was extremely effective at inhibiting cancer cell growth.
Meanwhile, Arizona's efforts to create an exchange are morphing into a political hot potato. Also in the news, WellPoint has purchased its own private exchange to compete with the state-run versions envisioned in the health law.
EpiCept Corporation announced today that it has entered into definitive agreements for the purchase of approximately 3.3 million shares of its common stock at $0.61 per share, and five-year warrants to purchase up to approximately 1.3 million shares of common stock at an exercise price of $0.56 per share, exercisable immediately.
Candidates gain votes by taking a "green" position on climate change - endorsing the existence of warming, human causation, and the need for taking action to address it, according to a new study of U.S. adults.
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
› Verified 5 days ago
Benjamin M Kalkin, SP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 6041 Cadillac Ave, Los Angeles, CA 90034 Phone: 323-857-2000 Fax: 626-405-6768 | |
Maureen Jennings, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2301 Roscomare Rd, #104, Los Angeles, CA 90077 Phone: 310-663-3868 | |
Ms. June Mitsunaga Fujimoto, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1968 W Adams Blvd Ste 300, Los Angeles, CA 90018 Phone: 310-553-3695 | |
Daniella Hay, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1080 S La Cienega Blvd Ste 208, Los Angeles, CA 90035 Phone: 323-426-6402 | |
Taryn Kiani Michiko Park, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1680 E 120th St, Los Angeles, CA 90059 Phone: 424-338-8000 | |
Franchesca Soto, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3200 Motor Ave, Los Angeles, CA 90034 Phone: 310-836-1223 | |
Ms. Jana Lovell, M.A, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11301 Wilshire Blvd, Los Angeles, CA 90073 Phone: 310-478-3711 |